Hamilton Thorne Receives Notification of Grant of Patent Right and CFDA Approval to Market Its LYKOS(R) Laser System in China
Marketwire Canada - Wed Jul 16, 7:20AM CDT
Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today announced that it has received notice that the China Food and Drug Administration (CFDA) has approved the Company's cutting edge LYKOS(R) for sale to clinical markets in China. Concurrent to this, the Company is pleased to announce it has received a Notification to Grant Patent Right for Invention covering the Modular Laser Assembly that is at the heart of its LYKOS system.
Hamilton Thorne & Halotech DNA SL to Preview New, Automated DNA Fragmentation Software ESHRE 2014
Marketwire Canada - Fri Jun 27, 8:15AM CDT
Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today announced that it will preview its new, automated DNA Fragmentation software at the European Society for Human Reproduction and Embryology meeting to be held in Munich from June 29 to July 2, 2014.
Hamilton Thorne Announces Annual and Special Meeting Voting Results
Marketwire - Wed Jun 18, 1:29AM CDT
Hamilton Thorne Ltd. (TSX VENTURE: HTL) ("Hamilton Thorne" or the "Company"
Hamilton Thorne Introduces Comprehensive Suite of Service and Support Offerings
Marketwire Canada - Mon Jun 16, 7:30AM CDT
Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today announced the introduction of a comprehensive suite of service plans, preventive maintenance and training offerings to support its hardware and software products.
Hamilton Thorne Engages Investor Relations Firm
Marketwire Canada - Mon Jun 16, 7:25AM CDT
Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today announced that it has engaged Investor Cubed Inc. ("Investor Cubed"
Hamilton Thorne Announces 2014 First Quarter Financial Results
Marketwire Canada - Wed May 28, 3:26PM CDT
Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today reported operational and financial results for the quarter ended March 31, 2014.
Hamilton Thorne Announces Stock Option Grants
Marketwire Canada - Fri Mar 21, 3:16PM CDT
Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today announced that it has granted a total of 1,450,000 stock options to purchase common shares pursuant to the Company's incentive stock option plan. The options are exercisable at Cdn$0.05 per share, and expire ten years from the date of grant. A total of 1,100,000 of these options were granted to the Company's Directors, CEO, CTO and CFO. Grants to non-employee Directors vest over three years; grants to employees vest over four years.
Hamilton Thorne Announces Preliminary 2013 Financial Results
Marketwire - Thu Feb 13, 7:30AM CST
Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today reported preliminary selected unaudited financial results for the fourth quarter and year-ended December 31, 2013.
Hamilton Thorne Announces 2013 Second Quarter Financial Results
Marketwire Canada - Mon Aug 26, 3:05PM CDT
Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today reported operational and financial results for the second quarter and six months year-to-date ended June 30, 2013.